Gustabor: Tailored AI Nutrition for Taste Changes During Cancer Therapy
Official title: Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
Run by Wuerzburg University Hospital · NCT07649681 · Data updated 2026-11-12
This trial tests whether personalized, AI-assisted dietary advice helps people with taste changes from cancer treatment compare to general dietary guidance.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 198 (estimated) |
| Sponsor | Wuerzburg University Hospital Academic / other |
| Locations | 6 sites (Augsburg, Bavaria and 5 other locations) |
| Status | Recruiting |
| Started | July 24, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT07649681 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with multiple myeloma, melanoma, urogenital cancers, or gastrointestinal cancers who have cancer-treatment–related taste disorders and can use an online nutrition portal.
✕Probably not a fit
Patients without taste changes or those unable to use the online portal or implement recipe suggestions may not benefit from the Gustabor approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized study compares an individualized Gustabor dietary program, supported by AI-generated recipe suggestions, with standard general dietary recommendations for patients experiencing taste changes during cancer therapy. Participants will have objective taste assessments and questionnaires to tailor dietary advice. The Gustabor group receives both general guidance and specific, taste-disorder–targeted suggestions, while the control group receives widely used oncology nutrition tips. The trial focuses on adults with multiple myeloma, melanoma, urogenital cancers, or GI cancers who are currently undergoing treatment and report taste disorders. Outcomes will inform whether personalized nutrition can improve nutritional intake and quality of life during cancer treatment.
Why it matters
Potential benefit: If successful, participants may experience improved taste function and better adherence to nutrition plans during cancer therapy.
How similar studies have gone: Previous nutrition-focused approaches have shown benefit in oncology; this study tests a novel AI-assisted, personalized method.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 * Suffering from one of the following tumor entities: Multiple myeloma, melanoma, urogenital cancer or malignant tumor of the gastrointestinal tract * Mainly oral nutrition * Subjectively perceived tumor therapy-related taste disorder * At least two clinical presentations planned within 12 weeks with a minimum interval of three weeks * Ability to participate in nutritional intervention, including use of the online portal and implementation of recipe suggestions (e.g. resources and access to a kitchen), either independently or with third-party support (e.g. by relatives, outpatient care services). Exclusion Criteria: * Pregnancy * Taste disorder explained by other causes (e.g. existing before therapy or COVID disease) * Placement in an inpatient care facility
Where it's running
-
Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany Recruiting -
LMU Klinikum Krebszentrum - CCC MünchenLMU - Comprehensive Cancer Center
München, Bavaria, Germany Recruiting -
Universitätsklinikum Augsburg
Augsburg, Bavaria, Germany Not yet recruiting -
Klinikum der Technischen Universität München (TUM Klinikum)
München, Bavaria, Germany Not yet recruiting -
Universitätsklinikum Regensburg
Regensburg, Bavaria, Germany Not yet recruiting -
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany Not yet recruiting
Study contacts
- Study coordinator: Prof. Dr. med. Alexander Hann
- Email: Hann_A@ukw.de
- Phone: +49 931 201 45918
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
ctDNA-guided stopping of immune therapy in advanced melanoma
This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
NeoAdjuvant PD-1–Based Therapy in Resectable Advanced Melanoma (NASA)
In people with resectable stage IIIB–IV melanoma, this study tests whether two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab given before surgery can keep people alive at 2 years without needing additional adjuvant therapy.
-
Cognitive changes after BCMA CAR-T in multiple myeloma
This study tests whether cognitive function changes over time in adults with relapsed or refractory multiple myeloma who receive BCMA CAR-T therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.